Sales of blockbuster weight-loss drugs have surged in 2024 and are projected to continue rising in the coming years. The ...

2024 was quite a year for significant strategic action among the pharmaceutical giants. Here are five key trends that will ...

Ever since the weight-loss properties of the GLP-1 agonist class of drugs - of which both Wegovy (semaglutide ... $399 per month (albeit without the auto-injector). I may have been premature ...

They also pointed to Lilly's focus on innovations such as a one-chamber auto-injector, which could further ... to rival injectable therapies like Wegovy, further cementing Lilly’s leadership ...

In the space of just a few months, the drug – designed originally to treat type 2 diabetes and sold under a variety of brand names, chiefly Ozempic and Wegovy ... is an auto-immune disease ...

Ozempic's patented semaglutide ingredient is also used in Novo's wildly popular obesity treatment Wegovy and diabetes tablets Rybelsus ... soared on robust demand for new weight-loss tablets and ...

The global auto-injectors market is on a significant growth trajectory, with market share expected to reach a robust valuation of USD 30,578.2 million in 2023. This figure represents a strong presence ...

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...